Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

AVRO

AVROBIO (AVRO)

AVROBIO Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AVRO
FechaHoraFuenteTítuloSímboloCompañía
21/05/202415:55Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:AVROAVROBIO Inc
09/05/202415:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVROAVROBIO Inc
05/05/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AVROAVROBIO Inc
27/02/202409:50PR Newswire (US)Kuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law FirmNASDAQ:AVROAVROBIO Inc
23/02/202415:00Edgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AVROAVROBIO Inc
05/02/202419:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVROAVROBIO Inc
01/02/202413:25PR Newswire (US)Kuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law FirmNASDAQ:AVROAVROBIO Inc
30/01/202415:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVROAVROBIO Inc
30/01/202407:00Business WireAVROBIO and Tectonic Therapeutic Announce MergerNASDAQ:AVROAVROBIO Inc
03/11/202315:15Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:AVROAVROBIO Inc
12/07/202306:00Business WireAVROBIO to Explore Strategic AlternativesNASDAQ:AVROAVROBIO Inc
14/06/202316:20Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:AVROAVROBIO Inc
12/06/202306:20Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVROAVROBIO Inc
12/06/202306:00Business WireAVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 MillionNASDAQ:AVROAVROBIO Inc
08/06/202315:32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVROAVROBIO Inc
07/06/202311:07Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:AVROAVROBIO Inc
22/05/202306:00Business WireAVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 MillionNASDAQ:AVROAVROBIO Inc
18/05/202307:14Dow Jones NewsAvrobio Stock Up 16% on Positive Data for Cystinosis TreatmentNASDAQ:AVROAVROBIO Inc
18/05/202306:00Business WireAVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual MeetingNASDAQ:AVROAVROBIO Inc
11/05/202306:00Business WireAVROBIO Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVROAVROBIO Inc
05/05/202315:01Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:AVROAVROBIO Inc
01/05/202316:02Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AVROAVROBIO Inc
01/05/202306:30Business WireAVROBIO Announces Leadership TransitionNASDAQ:AVROAVROBIO Inc
23/03/202315:59Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:AVROAVROBIO Inc
23/03/202315:37Edgar (US Regulatory)Annual Report (10-k)NASDAQ:AVROAVROBIO Inc
23/03/202306:00Business WireAVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business UpdateNASDAQ:AVROAVROBIO Inc
03/03/202306:00Business WireAVROBIO to Participate in Cowen’s 43rd Annual Health Care ConferenceNASDAQ:AVROAVROBIO Inc
09/02/202306:00Business WireAVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023NASDAQ:AVROAVROBIO Inc
08/02/202305:05Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AVROAVROBIO Inc
05/01/202306:00Business WireAVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AVROAVROBIO Inc
 Showing the most relevant articles for your search:NASDAQ:AVRO